| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
Spectral Diagnostics Inc., 135-2 The West Mall, Toronto, Ontario, Canada M9C 1C2.
a Author for correspondence. Fax 416 626-7383; e-mail qshi{at}ica.net
Background: Up to a 20-fold variation in serum cardiac troponin I (cTnI) concentration may be observed for a given patient sample with different analytical methods. Because more limited variation is seen for control materials and for purified cTnI, we explored the possibility that cTnI was present in altered forms in serum.
Methods: We used four recombinantly engineered cTnI fragments to study the regions of cTnI recognized by the Stratus®, Opus®, and ACCESS® immunoassays. The stability of these regions in serum was analyzed with Western blot.
Results: The measurement of several control materials and different forms of purified cTnI using selected commercial assays demonstrated five- to ninefold variation. Both the Stratus and Opus assays recognized the N-terminal portion (NTP) of cTnI, whereas the ACCESS assay recognized the C-terminal portion (CTP) of cTnI. Incubation of recombinant cTnI in normal human serum produced a marked decrease in cTnI concentration as determined with the ACCESS, but not the Stratus, immunoassay. Western blot analysis of the same samples using cTnI NTP- and CTP-specific antibodies demonstrated preferential degradation of the CTP of cTnI.
Conclusions: The availability of serum cTnI epitopes is markedly affected by the extent of ligand degradation. The N-terminal half of the cTnI molecule was found to be the most stable region in human serum. Differential degradation of cTnI is a key factor in assay-to-assay variation.© 1999 American Association for Clinical Chemistry
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  E. Kuhn, T. Addona, H. Keshishian, M. Burgess, D.R. Mani, R. T. Lee, M. S. Sabatine, R. E. Gerszten, and S. A. Carr Developing Multiplexed Assays for Troponin I and Interleukin-33 in Plasma by Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry Clin. Chem., June 1, 2009; 55(6): 1108 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Abramov, M. Abu-Tailakh, M. Frieger, A. Ganiel, D. Tuvbin, and A. Wolak Plasma Troponin Levels After Cardiac Surgery vs After Myocardial Infarction Asian Cardiovasc Thorac Ann, December 1, 2006; 14(6): 530 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Labugger, J. A. Simpson, M. Quick, H. A. Brown, C. E. Collier, I. Neverova, and J. E. Van Eyk Strategy for Analysis of Cardiac Troponins in Biological Samples with a Combination of Affinity Chromatography and Mass Spectrometry Clin. Chem., June 1, 2003; 49(6): 873 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Uettwiller-Geiger, A. H.B. Wu, F. S. Apple, A. W. Jevans, P. Venge, M. D. Olson, C. Darte, D. L. Woodrum, S. Roberts, and S. Chan Multicenter Evaluation of an Automated Assay for Troponin I Clin. Chem., June 1, 2002; 48(6): 869 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Venge, B. Lindahl, and L. Wallentin New Generation Cardiac Troponin I Assay for the Access Immunoassay System Clin. Chem., May 1, 2001; 47(5): 959 - 961. [Full Text] [PDF]
|
|
|
|
|
|
A. Lavoinne, B. Cauliez, H. Eltchaninoff, R. Koning, and A. Cribier Analytical and Clinical Performance of the Immulite Cardiac Troponin I Assay Clin. Chem., December 1, 2000; 46(12): 1989 - 1990. [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Jaffe, J. Ravkilde, R. Roberts, U. Naslund, F. S. Apple, M. Galvani, and H. Katus It's Time for a Change to a Troponin Standard Circulation, September 12, 2000; 102(11): 1216 - 1220. [Full Text] [PDF]
|
|
|
|
|
|
R. Labugger, L. Organ, C. Collier, D. Atar, and J. E. Van Eyk Extensive Troponin I and T Modification Detected in Serum From Patients With Acute Myocardial Infarction Circulation, September 12, 2000; 102(11): 1221 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Morrow, N. Rifai, M. J. Tanasijevic, D. R. Wybenga, J. A. de Lemos, and E. M. Antman Clinical Efficacy of Three Assays for Cardiac Troponin I for Risk Stratification in Acute Coronary Syndromes: A Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy Clin. Chem., April 1, 2000; 46(4): 453 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Ooi, P. A. Isotalo, and J. P. Veinot Correlation of Antemortem Serum Creatine Kinase, Creatine Kinase-MB, Troponin I, and Troponin T with Cardiac Pathology Clin. Chem., March 1, 2000; 46(3): 338 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Wilson, D. M. Laird, C. M. Forsythe, T. T. Biegalski, A. L. Keller, and R. J. Herrmann Antibody Selection for the Abbott AxSYM Troponin I Assay Clin. Chem., December 1, 1999; 45(12): 2293 - 2294. [Full Text] [PDF]
|
|
|
|
|
|
S. Liu, M. Y. Zhang, Q. Song, X. Zhang, L. Kadijevic, and Q. Shi Extra Leader Sequence Affects Immunoactivity of Cardiac Troponin I Clin. Chem., August 1, 1999; 45(8): 1300 - 1302. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
